MediWound (NASDAQ:MDWD) Upgraded by Zacks Research to Hold Rating

MediWound (NASDAQ:MDWD) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Wall Street Zen lowered MediWound from a “hold” rating to a “sell” rating in a research report on Friday, July 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, MediWound has an average rating of “Moderate Buy” and a consensus price target of $32.25.

MediWound Stock Performance

MediWound stock opened at $18.22 on Tuesday. MediWound has a fifty-two week low of $14.14 and a fifty-two week high of $22.50. The stock’s 50 day simple moving average is $17.95 and its two-hundred day simple moving average is $18.83. The stock has a market cap of $202.01 million, a price-to-earnings ratio of -6.90 and a beta of 0.22.

MediWound (NASDAQ:MDWD) last released its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.68). MediWound had a negative net margin of 142.18% and a negative return on equity of 96.71%. The firm had revenue of $5.71 million during the quarter, compared to analysts’ expectations of $5.68 million. On average, analysts predict that MediWound will post -2.66 earnings per share for the current year.

Hedge Funds Weigh In On MediWound

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. increased its holdings in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares in the last quarter. Corebridge Financial Inc. lifted its holdings in shares of MediWound by 17.1% during the first quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 665 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 999 shares during the last quarter. Deutsche Bank AG increased its holdings in MediWound by 2,255.2% in the 1st quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 6,044 shares in the last quarter. Finally, R Squared Ltd purchased a new position in MediWound in the 3rd quarter worth about $194,000. 46.83% of the stock is owned by institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.